SCHEMBL409574

SCHEMBL409574

O=C(O)c1onc(-c2ccccn2)c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.46
KDM4E B2RXH2 5/20 0.44
KDM6B O15054 1/20 0.44
KDM4A O75164 1/20 0.44
KDM5C P41229 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
KDM3A Q9Y4C1 1/20 0.44
GABRA5 P31644 1/20 0.44
PIN1 Q13526 1/20 0.41
LMNA P02545 3/20 0.41
P4HTM Q9NXG6 2/20 0.41
NAPRT Q6XQN6 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TP53 P04637 3/20 0.40
PKM P14618 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL408224 0.86 POLB (0.49) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL10111594 0.83 GABRA5 (0.48) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL12543755 0.83 GABRA5 (0.54) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL6315950 0.83 KDM4E (0.43) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL30684510 0.83 GABRA5 (0.54) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL27837002 0.80 ESR1 (0.41) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL408682 0.80 S1PR1 (0.45) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL6324765 0.79 TP53 (0.50) KDM4EKDM4ALMNATP53PKM
SCHEMBL2565912 0.78 PTPN1 (0.58) PTPN1KDM4ELMNASMN1; SMN2POLB
SCHEMBL536325 0.77 KDM4E (0.43) KDM4EKDM6BKDM4AKDM5CKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404672-B2 Substituted heterocyclic compounds BRISTOL-MEYERS SQUIBB COMPANY (US) 2013-03-26 US disclosed
US-20120022041-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-26 US disclosed
EP-2389377-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES Bristol-Myers Squibb Company (US) 2011-11-30 EP disclosed
US-8038731-B2 hair dyes contains naphthylimide thiol or disulphide groups; resistant and visible lightening effect on dark keratin fibres; cosmetics L'OREAL S.A. (FR) 2011-10-18 US disclosed
WO-2010085582-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022041-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS S1PR1, S1PR4, S1PR3 PTPN1 1701/4885KDM4E 3099/4885KDM6B 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.